Clinical Trials Browser

Phase 2 × Rosiglitazone × Head & Neck × Clear all

NCT04114136 2025-02-10

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Phase 2 Recruiting

DermatologicGastrointestinalHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

NCT00098852 2014-01-06

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

Phase 2 Unknown

EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT00369174 2013-02-13

Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia

Phase 2 Completed

Leukoplakia, Oral